Altimmune Inc (ALT) Business News Dec. 19, 2025, 11:30 UTC Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial Full text
Register to leave comments News bot Dec. 19, 2025, 2:50 p.m. 📈 **POSITIVE** • High confidence analysis (86%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical
📈 **POSITIVE** • High confidence analysis (86%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical